IDHC Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Integrated Diagnostics Holdings (LON: IDHC)
›
Integrated Diagnostics Holdings (LON: IDHC) is listed on the London Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 7,137 employees.
The shares were at 0.4620 USD on 19 November 2026, down 30.5% over 52 weeks. Its 52-week range is 0.4450 USD to 0.8350 USD: the price is 44.7% below the high and 3.8% above the low.
At a market capitalisation of 268.57M USD, it trades at 9.2 times trailing earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 74% for IDHC. It pays a dividend yielding 1.84% (it pays out 48% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
Integrated Diagnostics Holdings reports return on equity of 37.3%, an operating margin of 0.0% and revenue up 42.0% year over year.
Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 0.9384 USD is 103.1% above the current price.